Who are Enamel Matrix Derivative application's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/enamel-matrix-derivative-application.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Enamel Matrix Derivative application — Competitive Intelligence Brief

Enamel Matrix Derivative application (Enamel Matrix Derivative application) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biologic regenerative therapy. Area: Dentistry / Periodontics.

phase 3 Biologic regenerative therapy Amelogenins and enamel matrix proteins (non-receptor mediated cell signaling) Dentistry / Periodontics Small molecule Live · refreshed every 30 min

Target snapshot

Enamel Matrix Derivative application (Enamel Matrix Derivative application) — University of Pisa. Enamel Matrix Derivative promotes periodontal tissue regeneration by mimicking the natural proteins present during tooth development and stimulating the migration and differentiation of periodontal ligament cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Enamel Matrix Derivative application TARGET	Enamel Matrix Derivative application	University of Pisa	phase 3	Biologic regenerative therapy	Amelogenins and enamel matrix proteins (non-receptor mediated cell signaling)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biologic regenerative therapy class)

University of Pisa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enamel Matrix Derivative application — Competitive Intelligence Brief. https://druglandscape.com/ci/enamel-matrix-derivative-application. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab